Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 4/20 | 0.46 |
| ▸ | MMP1 | P03956 | 3/20 | 0.46 |
| ▸ | MMP9 | P14780 | 3/20 | 0.46 |
| ▸ | MMP12 | P39900 | 3/20 | 0.46 |
| ▸ | MDM2 | Q00987 | 4/20 | 0.40 |
| ▸ | MDM4 | O15151 | 3/20 | 0.40 |
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5648088 | 0.82 | MAPT (0.49) | MDM2MDM4MAPTNPC1RAB9A | |
| SCHEMBL4515793 | 0.76 | KDM4E (0.55) | KMT2A | |
| SCHEMBL5651378 | 0.71 | ALDH1A1 (0.50) | MDM2MAPTNPC1RAB9AKMT2A | |
| SCHEMBL25811868 | 0.64 | GCGR (0.48) | MMP2MMP1MMP9MMP12MAPT | |
| SCHEMBL20015818 | 0.60 | MAPT (0.59) | MAPTNPC1RAB9AKMT2A | |
| SCHEMBL6398360 | 0.60 | KMT2A (0.74) | MMP2MMP1MMP9MMP12ESR1 | |
| SCHEMBL6397540 | 0.60 | KMT2A (0.74) | MMP2MMP1MMP9MMP12ESR1 | |
| SCHEMBL11658262 | 0.59 | DRD2 (0.45) | MDM2MAPTNPC1RAB9A | |
| SCHEMBL20010798 | 0.59 | KDM4E (0.54) | MAPTNPC1RAB9AKMT2A | |
| SCHEMBL136005 | 0.59 | ALDH1A1 (0.64) | MMP2MMP1MMP9MMP12MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090149495-A1 | COMPOUNDS | RICHTER GEDEON NYRT. (HU) | 2009-06-11 | — | — | US | claimed |
| EP-1963336-A1 | NEW COMPOUNDS | Richter Gedeon NYRT (HU) | 2008-09-03 | — | — | EP | claimed |
| WO-2007072094-A1 | NEW COMPOUNDS | RICHTER GEDEON NYRT. (HU) | 2007-06-28 | — | — | WO | claimed |
| US-20090149495-A1 | COMPOUNDS | RICHTER GEDEON NYRT. (HU) | 2009-06-11 | — | — | US | disclosed |
| US-20090149495-A1 | COMPOUNDS | RICHTER GEDEON NYRT. (HU) | 2009-06-11 | — | — | US | disclosed |
| US-20090149495-A1 | COMPOUNDS | RICHTER GEDEON NYRT. (HU) | 2009-06-11 | — | — | US | disclosed |
| EP-1963336-A1 | NEW COMPOUNDS | Richter Gedeon NYRT (HU) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007072094-A1 | NEW COMPOUNDS | RICHTER GEDEON NYRT. (HU) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149495-A1 | COMPOUNDS | GRM3, GRM5, GRM1 | MMP2 4737/4885MMP1 4784/4885MMP9 4848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.